Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
- PMID: 37459141
- PMCID: PMC10352931
- DOI: 10.1001/jama.2023.13239
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Abstract
Importance: There are limited efficacious treatments for Alzheimer disease.
Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque.
Design, setting, and participants: Multicenter (277 medical research centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month phase 3 trial that enrolled 1736 participants with early symptomatic Alzheimer disease (mild cognitive impairment/mild dementia) with amyloid and low/medium or high tau pathology based on positron emission tomography imaging from June 2020 to November 2021 (last patient visit for primary outcome in April 2023).
Interventions: Participants were randomized in a 1:1 ratio to receive donanemab (n = 860) or placebo (n = 876) intravenously every 4 weeks for 72 weeks. Participants in the donanemab group were switched to receive placebo in a blinded manner if dose completion criteria were met.
Main outcomes and measures: The primary outcome was change in integrated Alzheimer Disease Rating Scale (iADRS) score from baseline to 76 weeks (range, 0-144; lower scores indicate greater impairment). There were 24 gated outcomes (primary, secondary, and exploratory), including the secondary outcome of change in the sum of boxes of the Clinical Dementia Rating Scale (CDR-SB) score (range, 0-18; higher scores indicate greater impairment). Statistical testing allocated α of .04 to testing low/medium tau population outcomes, with the remainder (.01) for combined population outcomes.
Results: Among 1736 randomized participants (mean age, 73.0 years; 996 [57.4%] women; 1182 [68.1%] with low/medium tau pathology and 552 [31.8%] with high tau pathology), 1320 (76%) completed the trial. Of the 24 gated outcomes, 23 were statistically significant. The least-squares mean (LSM) change in iADRS score at 76 weeks was -6.02 (95% CI, -7.01 to -5.03) in the donanemab group and -9.27 (95% CI, -10.23 to -8.31) in the placebo group (difference, 3.25 [95% CI, 1.88-4.62]; P < .001) in the low/medium tau population and -10.2 (95% CI, -11.22 to -9.16) with donanemab and -13.1 (95% CI, -14.10 to -12.13) with placebo (difference, 2.92 [95% CI, 1.51-4.33]; P < .001) in the combined population. LSM change in CDR-SB score at 76 weeks was 1.20 (95% CI, 1.00-1.41) with donanemab and 1.88 (95% CI, 1.68-2.08) with placebo (difference, -0.67 [95% CI, -0.95 to -0.40]; P < .001) in the low/medium tau population and 1.72 (95% CI, 1.53-1.91) with donanemab and 2.42 (95% CI, 2.24-2.60) with placebo (difference, -0.7 [95% CI, -0.95 to -0.45]; P < .001) in the combined population. Amyloid-related imaging abnormalities of edema or effusion occurred in 205 participants (24.0%; 52 symptomatic) in the donanemab group and 18 (2.1%; 0 symptomatic during study) in the placebo group and infusion-related reactions occurred in 74 participants (8.7%) with donanemab and 4 (0.5%) with placebo. Three deaths in the donanemab group and 1 in the placebo group were considered treatment related.
Conclusions and relevance: Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population.
Trial registration: ClinicalTrials.gov Identifier: NCT04437511.
Conflict of interest statement
Figures
Comment in
-
Ushering in a New Era of Alzheimer Disease Therapy.JAMA. 2023 Aug 8;330(6):503-504. doi: 10.1001/jama.2023.11701. JAMA. 2023. PMID: 37459123 No abstract available.
-
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.JAMA. 2023 Aug 8;330(6):507-509. doi: 10.1001/jama.2023.11703. JAMA. 2023. PMID: 37459124 No abstract available.
-
Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?JAMA. 2023 Aug 8;330(6):510-511. doi: 10.1001/jama.2023.11704. JAMA. 2023. PMID: 37459138 No abstract available.
-
Treatments for AD: towards the right target at the right time.Nat Rev Neurol. 2023 Oct;19(10):581-582. doi: 10.1038/s41582-023-00869-0. Nat Rev Neurol. 2023. PMID: 37658242 No abstract available.
-
Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.JAMA. 2023 Dec 19;330(23):2304-2305. doi: 10.1001/jama.2023.21109. JAMA. 2023. PMID: 38112817 No abstract available.
-
Use of Donanemab in Early Symptomatic Alzheimer Disease.JAMA. 2023 Dec 19;330(23):2304. doi: 10.1001/jama.2023.21106. JAMA. 2023. PMID: 38112820 No abstract available.
Similar articles
-
Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.Neurol Ther. 2024 Jun;13(3):677-695. doi: 10.1007/s40120-024-00604-x. Epub 2024 Apr 6. Neurol Ther. 2024. PMID: 38581616 Free PMC article.
-
How donanemab data address the coverage with evidence development questions.Alzheimers Dement. 2024 Apr;20(4):3127-3140. doi: 10.1002/alz.13700. Epub 2024 Feb 7. Alzheimers Dement. 2024. PMID: 38323738 Free PMC article. Review.
-
Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.Neurol Clin Pract. 2023 Apr;13(2):e200127. doi: 10.1212/CPJ.0000000000200127. Epub 2023 Feb 16. Neurol Clin Pract. 2023. PMID: 36891463 Free PMC article. Review.
-
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793. JAMA Neurol. 2022. PMID: 36094645 Free PMC article. Clinical Trial.
-
Donanemab in Early Alzheimer's Disease.N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13. N Engl J Med. 2021. PMID: 33720637 Clinical Trial.
Cited by
-
The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer's disease.Nat Aging. 2024 Jun;4(6):761-770. doi: 10.1038/s43587-024-00630-2. Epub 2024 Jun 5. Nat Aging. 2024. PMID: 38839924 Review.
-
Intermittent hypoxia training enhances Aβ endocytosis by plaque associated microglia via VPS35-dependent TREM2 recycling in murine Alzheimer's disease.Alzheimers Res Ther. 2024 Jun 3;16(1):121. doi: 10.1186/s13195-024-01489-6. Alzheimers Res Ther. 2024. PMID: 38831312 Free PMC article.
-
From bench to bedside: US-Japan Collaborative Workshop on the NVU.J Physiol Sci. 2024 May 30;74(Suppl 1):31. doi: 10.1186/s12576-024-00917-4. J Physiol Sci. 2024. PMID: 38816814 Free PMC article.
-
Single-domain antibody-based protein degrader for synucleinopathies.Mol Neurodegener. 2024 May 31;19(1):44. doi: 10.1186/s13024-024-00730-y. Mol Neurodegener. 2024. PMID: 38816762 Free PMC article.
-
Deep learning model for individualized trajectory prediction of clinical outcomes in mild cognitive impairment.Front Aging Neurosci. 2024 May 15;16:1356745. doi: 10.3389/fnagi.2024.1356745. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38813529 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous